Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explainer

Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.

Explainer

Semaglutide plus SGLT2 inhibitors in China

A Chinese real-world analysis described six-month metabolic outcomes in adults using semaglutide with an SGLT2 inhibitor.

29 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Tirzepatide and lithium safety signal

A 23-person cohort found a lithium safety signal after tirzepatide initiation in bipolar disorder. It cannot estimate the risk or prove causation.

29 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semaglutide, Low Testosterone, Nine Men

An exploratory study of nine men ties semaglutide to shifted DNA methylation in obesity-related low testosterone, and it is far too small to prove anything.

27 Sept 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

BPC-157 and TB-500, examined separately

BPC-157 and TB-500 get treated as a matched set online, but they are different molecules with separate, mostly animal-only evidence and neither is approved.

26 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

GLP-1 Drugs and Kidney Outcomes in CKD

Thirteen GLP-1 receptor agonist trials pooled in chronic kidney disease show fewer heart and kidney events, with semaglutide topping an exploratory ranking.

26 Sept 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Tirzepatide May Ease Beta-Cell Hypoxia

A mouse and cell study finds tirzepatide, GLP-1, and GIP suppress high-glucose-induced beta-cell hypoxia through a cAMP/PKA pathway.

26 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Missed Doses of Oral vs Weekly Semaglutide

A Novo Nordisk research letter models what missing doses does to drug levels for oral semaglutide versus once-weekly GLP-1 injections.

26 Sept 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

PT-141 for male ED: what the FDA says

PT-141 is FDA-approved for low sexual desire in premenopausal women, not male erectile dysfunction, and the off-label male use has far thinner evidence.

26 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

An RNA Therapy for Muscle Loss on GLP-1s

In mice, a new RNA-based therapy paired with semaglutide preserved more lean mass than semaglutide alone, though it remains far from human use.

26 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semaglutide in Children: England's Data

A corrected conference abstract from 35 English specialist clinics reports how 406 children and young people fared on semaglutide.

26 Sept 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Semaglutide and Heart-Failure Hemodynamics

A new case report describes semaglutide easing heart-failure pressures in one patient, but a single case can't prove a population-wide effect.

26 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Why Semax Comes as a Nasal Spray

Semax is a Russian-registered nasal-spray peptide with no FDA or EU approval. Here is what the intranasal evidence actually supports.

26 Sept 2026 · PeptideMethods Editorial Team · 4 min read